Aardvark Therapeutics, Inc. Common Stock
AARDNASDAQHealthcareBiotechnology
Previous close
$6.82
+$0.93 · +15.79%
AARD company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
31
Expensive
Momentum
54
Neutral
Sentiment
41
Mixed
Risk resilience
7
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Tien-Li Lee
- Listed since
- Feb 13, 2025
- Employees
- 28
Market position
Day range
Current $6.82
52-week range
Current $6.82
- Open
- $6.205
- Previous close
- $5.89
- Volume
- 173.69K
- 0.75× average
- Average volume
- 231.12K
- Average daily volume
- Market cap
- 149.25M USD
- Beta
- 3.81
- Market reference 1
- 50-day average
- $5.8899
- +15.79% above average
- 200-day average
- $8.1734
- -16.56% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 239.83M USD
- P/E (TTM)
- -2.12×
- P/B (TTM)
- 1.99×
- P/S (TTM)
- 0×
- EV / EBITDA
- -4.17×
- Earnings yield
- -20.11%
- Free cash flow yield
- -18.95%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -54.01%
- Return on assets
- -49.15%
- Return on invested capital
- -58.58%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 10.61×
Earnings
- EPS beat rate
- 43%
- 3 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -0.26%
- 7 comparable reports
- Latest EPS result
- -0.66
- Estimate -0.87 · Beat by 24.52%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.50
34.02% downsideAARD news
AARD peers
ETFs holding AARD
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.7M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF926.57K0.00%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB552.33K0.01%10.75B USD0.44%$213.56+1.29%
iShares Micro-Cap ETFIWC268.89K0.02%1.53B USD0.60%$198.39+1.10%
Invesco Nasdaq Biotechnology ETFIBBQ7.48K0.01%94.57M USD0.19%$36.29+1.37%
ProShares Ultra Nasdaq BiotechnologyBIB5.09K0.00%103.78M USD1.19%$122.16+2.73%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 2.7M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 926.57K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 552.33K
- Weight
- 0.01%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
iShares Micro-Cap ETFIWC- Market value
- 268.89K
- Weight
- 0.02%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Invesco Nasdaq Biotechnology ETFIBBQ- Market value
- 7.48K
- Weight
- 0.01%
- AUM
- 94.57M USD
- Expense ratio
- 0.19%
- Price / 1D
- $36.29+1.37%
ProShares Ultra Nasdaq BiotechnologyBIB- Market value
- 5.09K
- Weight
- 0.00%
- AUM
- 103.78M USD
- Expense ratio
- 1.19%
- Price / 1D
- $122.16+2.73%
Continue in GoAI
Research AARDresearch.disclaimer